510 related articles for article (PubMed ID: 32133835)
1. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
3. Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats.
Malikowska-Racia N; Koniewski M; Golebiowska J; Popik P
J Psychopharmacol; 2023 Nov; 37(11):1149-1156. PubMed ID: 37842884
[TBL] [Abstract][Full Text] [Related]
4. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
5. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
[TBL] [Abstract][Full Text] [Related]
6. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice.
Qu Y; Chang L; Ma L; Wan X; Hashimoto K
Pharmacol Biochem Behav; 2023 Jan; 222():173500. PubMed ID: 36476377
[TBL] [Abstract][Full Text] [Related]
7. Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?
Hashimoto K
Eur Arch Psychiatry Clin Neurosci; 2024 Feb; ():. PubMed ID: 38411629
[TBL] [Abstract][Full Text] [Related]
8. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
[TBL] [Abstract][Full Text] [Related]
9. The possible place for psychedelics in pharmacotherapy of mental disorders.
Wojtas A
Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
[TBL] [Abstract][Full Text] [Related]
10. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
11. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
[TBL] [Abstract][Full Text] [Related]
12. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
[TBL] [Abstract][Full Text] [Related]
13. Role of Psychedelics in Treatment-Resistant Depression.
Kamal S; Jha MK; Radhakrishnan R
Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
[TBL] [Abstract][Full Text] [Related]
14. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
Bottemanne H; Claret A; Fossati P
Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
[TBL] [Abstract][Full Text] [Related]
15. Rapid-acting antidepressants.
Witkin JM; Martin AE; Golani LK; Xu NZ; Smith JL
Adv Pharmacol; 2019; 86():47-96. PubMed ID: 31378256
[TBL] [Abstract][Full Text] [Related]
16. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
[TBL] [Abstract][Full Text] [Related]
17. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.
Aleksandrova LR; Phillips AG
Trends Pharmacol Sci; 2021 Nov; 42(11):929-942. PubMed ID: 34565579
[TBL] [Abstract][Full Text] [Related]
18. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
20. Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.
Popik P; Hogendorf A; Bugno R; Khoo SY; Zajdel P; Malikowska-Racia N; Nikiforuk A; Golebiowska J
Psychopharmacology (Berl); 2022 Jun; 239(6):1689-1703. PubMed ID: 35234983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
